Firms

Neuro.VC

San Francisco Bay Area, California, United States

Neuro.VC is a neurodegeneration-focused venture investment firm publicly corroborated by portfolio-company financing disclosures and founder biographies. It invests in therapeutic approaches for Alzheimer’s disease, Parkinson’s disease and ALS. The University of Alabama and the Michael J. Fox Foundation identify Adam Knight, PhD as cofounder and partner; he previously founded and led Neuron23, working in precision neurology and genetically defined disease. Its commissioned brand designer Cardigan identifies John Doerr as a cofounder, independently distinguishing the institution from similarly named NeuroVentures or NeuronVC businesses. Capsida’s own May2025 corporate deck explicitly names NEURO.VC against a12MUSD convertible note in2023, establishing actual institutional financing rather than a guessed personal founder check. A2025 peer-reviewed conflict-of-interest statement names Vanqua Bio, Neuron23 and Capsida as institutional investments; exact rounds for the first two are not inferred. A current public self-profile discloses Omer Siddiqui’s Neuro.VC affiliation without an operating title, and Jeito’s current biography identifies Elana Lockshin’s prior investment experience with Neuro.VC. No complete current staff directory, exact legal LLC/LP entity, regulatory manager registration, verified operational website or fund-close size was identified in the reviewed primary sources. The matching neuro.vc address currently redirects to a parked landing page and is not asserted as the operational website. These coverage gaps remain explicit.

Founded

—

Type

Venture capital

Team

Operations and support

Adam KnightCo-Founder and Partner

Elana LockshinFormer Investment Affiliation (title unpublished)

John DoerrCo-Founder (commissioned brand case-study disclosure)

Omer SiddiquiDisclosed Affiliation (operating title unpublished)

SHOW MORE

Investments

$12MUnknown date

Capsida Biotherapeutics

Neuro.VC

SHOW MORE